Literature DB >> 15259089

Hepatitis B virus reactivation in a patient undergoing steroid-free chemotherapy.

Daisuke Shimizu1, Kenichi Nomura, Yosuke Matsumoto, Kyoji Ueda, Kanji Yamaguchi, Masahito Minami, Yoshito Itoh, Shigeo Horiike, Masuji Morita, Masafumi Taniwaki, Takeshi Okanoue.   

Abstract

A 62-year-old Japanese man who was positive for hepatitis B surface antigen (HBsAg) and anti-HBe antibody, underwent chemotherapy for non-Hodgkin's lymphoma (NHL). Mutations were detected in the precore region (nt1896) of HBV. Because steroid-containing regimen may cause reactivation of hepatitis B virus (HBV) and hepatitis may progress to be fulminant after its withdrawal, we administered CHO (CPA, DOX and VCR) therapy and the patient obtained complete response. However, he developed acute exacerbation of hepatitis due to HBV reactivation. Recovery was achieved with lamivudine (100 mg/d) and plasma exchange. The present case suggests that acute exacerbation of hepatitis can occur with steroid-free regimen. Because the efficacy of the prophylactic use of lamivudine has been reported and the steroid enhances curability of malignant lymphoma, the steroid containing regimen with prophylaxis of lamivudine should be evaluated further.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15259089      PMCID: PMC4724963          DOI: 10.3748/wjg.v10.i15.2301

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  8 in total

1.  Efficacy of lamivudine to prevent hepatitis reactivation in hepatitis B virus-infected patients treated for non-Hodgkin lymphoma.

Authors:  Marcello Persico; Fedele De Marino; Giovanni Di Giacomo Russo; Aristide Morante; Bruno Rotoli; Roberto Torella; Amalia De Renzo
Journal:  Blood       Date:  2002-01-15       Impact factor: 22.113

2.  Treatment of HBV-carrying lymphoma patients with Rituximab and CHOP: a diagnostic and therapeutic challenge.

Authors:  C Skrabs; C Müller; H Agis; C Mannhalter; U Jäger
Journal:  Leukemia       Date:  2002-09       Impact factor: 11.528

3.  Reactivation of precore mutant hepatitis B virus in chemotherapy-treated patients.

Authors:  M S Dai; J J Lu; Y C Chen; C L Perng; T Y Chao
Journal:  Cancer       Date:  2001-12-01       Impact factor: 6.860

4.  Acute exacerbation of hepatitis due to reactivation of hepatitis B virus with mutations in the core region after chemotherapy for malignant lymphoma.

Authors:  T Sato; J Kato; J Kawanishi; K Kogawa; M Ohya; S Sakamaki; Y Niitsu
Journal:  J Gastroenterol       Date:  1997-10       Impact factor: 7.527

5.  Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection.

Authors:  W F Carman; M R Jacyna; S Hadziyannis; P Karayiannis; M J McGarvey; A Makris; H C Thomas
Journal:  Lancet       Date:  1989-09-09       Impact factor: 79.321

6.  Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy.

Authors:  G Rossi; A Pelizzari; M Motta; M Puoti
Journal:  Br J Haematol       Date:  2001-10       Impact factor: 6.998

7.  Lamivudine allows completion of chemotherapy in lymphoma patients with hepatitis B reactivation.

Authors:  F Silvestri; A Ermacora; A Sperotto; F Patriarca; F Zaja; D Damiani; R Fanin; M Baccarani
Journal:  Br J Haematol       Date:  2000-02       Impact factor: 6.998

8.  Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma.

Authors:  Ann-Lii Cheng; Chao A Hsiung; Ih-Jen Su; Pei-Jer Chen; Ming-Chih Chang; Chao-Jung Tsao; Woei-Yao Kao; Wu-Ching Uen; Chih-Hung Hsu; Hwei-Fan Tien; Tsu-Yi Chao; Li-Tzong Chen; Jacqueline Whang-Peng
Journal:  Hepatology       Date:  2003-06       Impact factor: 17.425

  8 in total
  1 in total

1.  Screening for hepatitis B in patients with lymphoma.

Authors:  Jonathan Ramirez; Anupama Thadareddy Duddempudi; Moazzam M Sana; Syed S Hasan; Mario de Los Santos; Juhee Song; Ying Fang-Hollingsworth; Sandeep S Gupta; Dawn M Sears
Journal:  Proc (Bayl Univ Med Cent)       Date:  2015-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.